Using machine perfusion to improve liver transplant outcomes for patients with liver cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the impact of hypothermic machine perfusion on liver grafts prior to transplantation in patients with hepatocellular carcinoma (HCC). The approach aims to enhance graft survival and reduce complications by mitigating ischemia-reperfusion injury through advanced perfusion techniques. By identifying biomarkers that predict graft outcomes, the study seeks to provide a non-invasive method for assessing graft health before transplantation. The research focuses on patients who meet specific criteria for liver transplantation and utilizes mass spectrometry-based metabolomics for analysis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with HCC within Milan criteria at listing candidate for liver transplantation
* ECOG 0-2
* DBD donors
* capability to sign an informed consent

Exclusion Criteria:

* pediatric patients
* DCD donors
* DBD extended criteria requiring machine perfusion (no ethical randomization)
* living donor liver transplantation
* split liver

Where it's running

• AOU di Modena
  Modena, Mo, Italy Recruiting

Study contacts

• Principal investigator: Eduardo M Sommella — University of Salerno
• Study coordinator: Paolo Magistri, MD FACS
• Email: paolo.magistri@unimore.it
• Phone: +390594225265

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Identifying Prognostic Factors for Liver Disease and Transplant Needs

  This study is trying to find out which factors can help predict if people with certain liver diseases will need a transplant or develop liver cancer.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, Bologna · NCT06813508

• Using cabozantinib to treat liver cancer that has returned after transplant

  This study is testing if cabozantinib can help people with liver cancer that has come back after a liver transplant.

  Recruiting Phase 2 University Health Network, Toronto · Toronto, Ontario · NCT04204850

• InstaSure Non-Invasive Finger-Press Test for HCC

  This study tests a non-invasive finger-skin test to help identify hepatocellular carcinoma in adults.

  Recruiting Beijing Municipal Administration of Hospitals · Beijing, Beijing Municipality · NCT07848750

• BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer

  This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.

  Recruiting at 2 sites Phase 3 BeOne Medicines · South Brisbane, Queensland and 1 other locations · NCT07836530

• Zinc add-on with targeted therapy plus immunotherapy for advanced liver cancer

  This study tests whether adding daily zinc to standard targeted therapy and immunotherapy helps people with unresectable or advanced hepatocellular carcinoma.

  Recruiting Phase 2 Anhui Provincial Hospital · Hefei, Anhui · NCT07793695

• Expanding HIV-positive donor livers for HIV-positive recipients

  This study tests whether liver transplants from HIV-positive donors to HIV-positive recipients are safe regarding opportunistic infections and cancer.

  Recruiting at 2 sites National Institute of Allergy and Infectious Diseases (NIAID) · Baltimore, Maryland and 1 other locations · NCT07778459

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.